Tango reports 92% response rate in pancreatic cancer trial, plans Phase 3 study

Filed June 8, 2026 · Period ending June 8, 2026 · ~1 min read

Key Changes

• high

  Phase 1/2 trial of vopimetostat plus daraxonrasib achieved 92% response rate in 12 pancreatic cancer patients, with 90% progression-free at six months and 100% disease control—exceptionally strong results for heavily pre-treated metastatic disease.

  Item 7.01: Press Release verify on EDGAR →
• high

  Company plans to advance vopimetostat plus daraxonrasib into Phase 3 randomized controlled trial for first-line pancreatic cancer and explore registration pathways for second-line treatment, pending regulatory feedback.

  Item 7.01: Press Release verify on EDGAR →
• high

  Combination therapy showed manageable safety profile with mostly mild-to-moderate side effects, no treatment discontinuations, and no severe (grade 4 or 5) treatment-related adverse events across dose levels.

  Item 7.01: Press Release verify on EDGAR →